Total Payments
$4,348
2024 Payments
$630.45
Companies
32
Transactions
162
Medicare Patients
93,727
Medicare Billing
$5.4M
Payment Breakdown by Category
Food & Beverage$4,187 (96.3%)
Education$160.95 (3.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,187 | 160 | 96.3% |
| Education | $160.95 | 2 | 3.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $576.40 | 26 | $0 (2024) |
| ABBVIE INC. | $553.21 | 20 | $0 (2024) |
| Janssen Biotech, Inc. | $460.11 | 20 | $0 (2022) |
| Dendreon Pharmaceuticals LLC | $454.33 | 11 | $0 (2022) |
| Blue Earth Diagnostics Limited | $314.52 | 6 | $0 (2024) |
| Amgen Inc. | $209.38 | 9 | $0 (2019) |
| Bayer Healthcare Pharmaceuticals Inc. | $188.86 | 5 | $0 (2023) |
| Augmenix, Inc. | $155.93 | 2 | $0 (2018) |
| MEDIVATION FIELD SOLUTIONS LLC | $139.14 | 7 | $0 (2018) |
| Astellas Pharma US Inc | $120.08 | 7 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $630.45 | 26 | PFIZER INC. ($165.73) |
| 2023 | $567.98 | 18 | PFIZER INC. ($190.18) |
| 2022 | $536.22 | 23 | ABBVIE INC. ($138.50) |
| 2021 | $439.84 | 21 | AbbVie Inc. ($95.35) |
| 2020 | $127.72 | 5 | Dendreon Pharmaceuticals LLC ($67.74) |
| 2019 | $494.69 | 19 | Janssen Biotech, Inc. ($214.13) |
| 2018 | $1,150 | 33 | Dendreon Pharmaceuticals LLC ($192.98) |
| 2017 | $401.43 | 17 | Blue Earth Diagnostics Limited ($110.58) |
All Payment Transactions
162 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/27/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $34.10 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/13/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 10/15/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2024 | Blue Earth Diagnostics Limited | POSLUMA (Drug) | Food and Beverage | In-kind items and services | $34.58 | General |
| Category: Diagnostic Imaging | ||||||
| 10/11/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $32.23 | General |
| Category: UROTHELIAL CANCER | ||||||
| 09/25/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2024 | Blue Earth Diagnostics Limited | POSLUMA (Drug) | Food and Beverage | In-kind items and services | $28.95 | General |
| Category: Diagnostic Imaging | ||||||
| 09/19/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $33.87 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 09/19/2024 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $11.65 | General |
| Category: ENDOCRINOLOGY | ||||||
| 09/10/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: ONCOLOGY | ||||||
| 08/27/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $14.86 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $23.57 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $20.23 | General |
| Category: ENDOCRINOLOGY | ||||||
| 07/22/2024 | Blue Earth Diagnostics Limited | POSLUMA (Drug) | Food and Beverage | In-kind items and services | $26.91 | General |
| Category: Diagnostic Imaging | ||||||
| 07/18/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $23.92 | General |
| Category: HORMONE THERAPY | ||||||
| 07/15/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: ONCOLOGY | ||||||
| 07/10/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $24.18 | General |
| Category: ONCOLOGY | ||||||
| 06/10/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $24.55 | General |
| Category: ONCOLOGY | ||||||
| 05/22/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 05/20/2024 | Laborie Medical Technologies Corp. | Optilume BPH Drug Coated Balloon Catheter (Device) | Food and Beverage | Cash or cash equivalent | $43.06 | General |
| Category: Urology | ||||||
| 05/01/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $34.22 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 04/24/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: ONCOLOGY | ||||||
| 03/19/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $22.98 | General |
| Category: ONCOLOGY | ||||||
| 02/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: ONCOLOGY | ||||||
| 01/24/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $23.09 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 79 | 23,560 | 83,174 | $6.2M | $1.4M |
| 2022 | 79 | 25,644 | 86,995 | $6.5M | $1.5M |
| 2021 | 72 | 24,748 | 82,998 | $6.2M | $1.5M |
| 2020 | 67 | 19,775 | 74,186 | $4.6M | $1.0M |
Total Patients
93,727
Total Services
327,353
Medicare Billing
$5.4M
Procedure Codes
297
All Medicare Procedures & Services
297 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 970 | 2,742 | $1.1M | $274,100 | 25.0% |
| 52281 | Dilation of urethra using an endoscope | Office | 2023 | 189 | 363 | $436,200 | $105,925 | 24.3% |
| 76856 | Complete ultrasound scan of pelvis | Office | 2023 | 584 | 1,058 | $449,650 | $100,802 | 22.4% |
| 76775 | Limited ultrasound scan behind abdominal cavity | Office | 2023 | 759 | 1,373 | $412,150 | $64,797 | 15.7% |
| 82670 | Measurement of total estradiol (hormone) | Office | 2023 | 827 | 1,951 | $175,590 | $53,206 | 30.3% |
| 84403 | Testosterone (hormone) level, total | Office | 2023 | 840 | 2,006 | $190,570 | $50,606 | 26.6% |
| 84270 | Sex hormone binding globulin (protein) level | Office | 2023 | 828 | 1,952 | $185,440 | $41,453 | 22.4% |
| 76857 | Limited ultrasound scan of pelvis | Office | 2023 | 607 | 960 | $407,025 | $40,758 | 10.0% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 354 | 421 | $178,925 | $38,987 | 21.8% |
| 84146 | Prolactin (milk producing hormone) level | Office | 2023 | 823 | 1,938 | $135,660 | $36,718 | 27.1% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 839 | 2,000 | $140,000 | $35,942 | 25.7% |
| 87798 | Detection test by nucleic acid for organism, amplified probe technique | Office | 2023 | 64 | 1,040 | $104,000 | $35,764 | 34.4% |
| 83001 | Gonadotropin, follicle stimulating (reproductive hormone) level | Office | 2023 | 827 | 1,948 | $136,360 | $35,390 | 26.0% |
| 83002 | Gonadotropin, luteinizing (reproductive hormone) level | Office | 2023 | 825 | 1,930 | $96,500 | $34,936 | 36.2% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 862 | 1,976 | $98,800 | $32,389 | 32.8% |
| J3490 | Unclassified drugs | Office | 2023 | 23 | 361 | $91,500 | $29,955 | 32.7% |
| 86316 | Analysis for detection of tumor marker | Office | 2023 | 495 | 1,061 | $95,490 | $21,560 | 22.6% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 28 | 153 | $95,625 | $20,859 | 21.8% |
| 84154 | Psa (prostate specific antigen) measurement, free | Office | 2023 | 528 | 1,151 | $103,590 | $20,664 | 19.9% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 849 | 1,869 | $93,450 | $17,717 | 19.0% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 862 | 1,974 | $98,700 | $17,415 | 17.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 885 | 2,039 | $40,780 | $17,090 | 41.9% |
| 80069 | Kidney function blood test panel | Office | 2023 | 872 | 2,004 | $100,200 | $17,037 | 17.0% |
| 76872 | Ultrasound scan of pelvic region through rectum | Office | 2023 | 118 | 130 | $39,000 | $16,333 | 41.9% |
| 80076 | Liver function blood test panel | Office | 2023 | 865 | 1,981 | $59,430 | $15,821 | 26.6% |
About Dr. Stephen Sacks, MD
Dr. Stephen Sacks, MD is a Urology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1073543369.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Sacks, MD has received a total of $4,348 in payments from pharmaceutical and medical device companies, with $630.45 received in 2024. These payments were reported across 162 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($4,187).
As a Medicare-enrolled provider, Sacks has provided services to 93,727 Medicare beneficiaries, totaling 327,353 services with total Medicare billing of $5.4M. Data is available for 4 years (2020–2023), covering 297 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Los Angeles, CA
- Active Since 07/03/2006
- Last Updated 12/07/2010
- Taxonomy Code 208800000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1073543369
Products in Payments
- XTANDI (Drug) $848.86
- PROVENGE (Drug) $454.33
- Erleada (Drug) $362.84
- BOTOX (Biological) $271.23
- Axumin (Drug) $224.08
- Prolia (Biological) $209.38
- Nubeqa (Drug) $188.86
- LUPRON DEPOT (Drug) $167.01
- SpaceOAR (Device) $155.93
- ORGOVYX (Drug) $151.87
- ZYTIGA (Drug) $123.86
- Lupron (Drug) $104.47
- KEYTRUDA (Biological) $101.84
- POSLUMA (Drug) $90.44
- Tulsa-Pro (Device) $88.19
- PYLARIFY (Drug) $74.20
- ERLEADA (Drug) $73.36
- ADSTILADRIN (Biological) $67.21
- Xtandi (Drug) $62.76
- LYNPARZA (Drug) $54.93
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Los Angeles
Mihir Desai, M.d, M.D
Urology — Payments: $1.6M
Urology $1.6M
Arie Belldegrun, Md, MD
Urology — Payments: $1.3M
Urology $1.3M
Dr. William Aronson, Md, MD
Urology — Payments: $753,306
Urology $753,306
Dr. Stuart Holden
Urology — Payments: $668,127
Urology $668,127
Dr. Siamak Daneshmand, M.d, M.D
Urology — Payments: $317,876
Urology $317,876
Dr. Jeffrey Loh-Doyle, M.d, M.D
Urology — Payments: $295,721
Urology $295,721